DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
SELLAS Life Sciences (SLS) – WT1 AML Vaccine & CDK9 Inhibitor Deep Dive
Bilingual EN/IT deep dive on SELLAS Life Sciences Group (NASDAQ: SLS): GPS Phase 3 REGAL AML vaccine, SLS009 CDK9 inhibitor (ASH 2025), survival-driven catalyst, social/retail sentiment, analyst targets, balance sheet and risk map. Informational only – not investment advice.
Ticker SLS (NASDAQ)
Sector Oncology / Immunotherapy
Stage Late-stage clinical
Core AML maintenance & CDK9
News of the day / Notizia del giorno
SELLAS has presented detailed Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed/refractory AML-MR at ASH 2025: overall response rates in the mid-40% range (higher in less pre-treated patients) and median overall survival substantially above historical benchmarks in this high-risk population.
In parallel, the pivotal Phase 3 REGAL trial of GPS in AML has passed an event-driven (60 deaths) interim analysis for efficacy, futility and safety, with the IDMC recommending continuation without modification; the final OS analysis at 80 deaths is anticipated by year-end 2025.
Executive Summary (EN)
SELLAS Life Sciences is a late-stage oncology biotech whose near-term equity story is dominated by a single survival-driven Phase 3 trial (REGAL with GPS in AML maintenance) and a rapidly de-risking CDK9 program (SLS009 in AML-MR).
- GPS (Galinpepimut-S) – WT1-targeted multi-peptide vaccine. In AML CR2, Phase 2 data showed median OS of 21.0 vs 5.4 months vs control (p<0.02). REGAL is a 1:1 randomized OS-driven Phase 3 trial in CR2/CR2p patients, with an IDMC-cleared interim and final analysis expected by YE 2025.
- SLS009 (tambiciclib) – highly selective CDK9 inhibitor. Phase 2 expansion in r/r AML-MR after venetoclax-based therapy delivered ORR in the 40–50% range and median OS roughly triple historic outcomes in the least pre-treated cohort, with a manageable safety profile.
- Balance sheet – ≈44.3M USD cash at 30 Sep 2025 plus ≈29.1M USD from warrant exercises in Oct 2025 (~73M total liquidity), net loss ~19.2M USD for 9M 2025, no material financial debt.
- Positioning – high retail following, very active options market (call-heavy), and elevated short interest. This is a classic high-beta catalyst name, not a quiet deep-value story.
- Analyst targets – external 12-month targets cluster around 6–7.5 USD (average ≈6.8–7.1 USD), implying large upside if REGAL and SLS009 deliver, but these are scenario-based, not guarantees.
This report is strictly informational. It maps data, social/retail sentiment, and risk; it is not an invitation to buy or sell SLS.
1. Company overview & strategy
SELLAS positions itself at the intersection of cancer immunotherapy (WT1 vaccines) and transcription-targeting small molecules (CDK9). Its near-term fate is dominated by REGAL, but the mid-term strategic plan clearly contemplates GPS combinations and SLS009 in multiple AML subsets and possibly in solid tumors.
GPS is licensed from Memorial Sloan Kettering Cancer Center. SLS009 is in-licensed from GenFleet Therapeutics for territories outside Greater China. A separate deal with 3D Medicines grants regional rights to GPS/GPS+ in Greater China, with potential milestones and royalties if development is successful. This structure gives SELLAS global optionality without committing to build a full ex-US commercial infrastructure on its own.
Overall, SELLAS is a classic late-stage biotech: highly binary at the clinical level, but with credible science and partners surrounding its two core assets.
2. Pipeline deep dive – GPS, SLS009, combinations
2.1 GPS – WT1 vaccine
Mechanism: multi-peptide vaccine presenting multiple WT1 epitopes to generate both CD4+ and CD8+ immune responses against WT1-expressing blasts. WT1 is over-expressed in AML and various solid tumors, making it a target of interest across indications.
Phase 2 AML CR2: SELLAS has reported median OS of 21.0 months for GPS vs 5.4 months in control, with p-values around 0.02. Safety was acceptable, dominated by injection-site reactions and low-grade systemic events. These data underpinned the move into Phase 3.
Solid tumors: GPS has shown preliminary activity in:
- WT1-positive platinum-resistant ovarian cancer in combination with pembrolizumab (Keytruda).
- Malignant pleural mesothelioma in combination with nivolumab (Opdivo), with OS and PFS signals above historical controls.
These early studies are small and primarily hypothesis-generating, but they demonstrate that WT1 vaccination can synergize with checkpoint blockade and may support future label expansions if AML is de-risked first.
2.2 SLS009 – CDK9 inhibitor
Mechanism: SLS009 targets CDK9, a key regulator of transcription for pro-survival genes such as MCL1. Many high-risk AML clones rely on such pathways; CDK9 inhibition offers a rational strategy to resensitize them to apoptotic cues.
Phase 2 AML-MR (ASH 2025): the combination of SLS009 + azacitidine + venetoclax in relapsed/refractory AML with MDS-related changes (post VEN-based therapy) showed:
- Overall response rates in the mid-40% range (CR+CRi+MLFS), higher in patients with fewer prior lines.
- Median OS in the least pre-treated cohort around 9 months vs ~2.5–3 months historically.
- Very adverse baseline genetics (ASXL1, RUNX1, TP53, SRSF2 and ELN adverse-risk) with no dose-limiting toxicities at the 30 mg BIW dose.
SLS009 has already met its internal proof-of-concept bars and carries Orphan/Fast Track designations in some indications. SELLAS is preparing expansion into front-line AML settings, which, if successful, could significantly increase the long-term value of the CDK9 franchise.
3. Next major catalyst – REGAL final OS readout
REGAL is an OS-driven, event-based trial. After the interim at 60 deaths, the next analysis will occur at 80 deaths, which SELLAS guides as expected by the end of 2025. From a trading perspective this is the key date window: the exact day may surprise, but the readout is unlikely to drift far outside that band unless survival curves extend substantially.
Because REGAL is randomized and OS-driven, there are no “soft” endpoints to massage. If GPS meaningfully improves OS vs BAT with a tolerable safety profile, the result will be clinically relevant; if it does not, the trial will be viewed as a miss. Even borderline-positive outcomes will be debated; regulatory path and real-world uptake would then become the central questions.
The presence of:
- Elevated short interest,
- Very call-skewed options flow,
- High social/retail attention,
means that volatility around REGAL is almost guaranteed – the only unknown is direction and magnitude.
4. Social & retail sentiment – Stocktwits, Reddit, options, X
4.1 Stocktwits & social hubs
On Stocktwits, SLS has tens of thousands of watchers and frequent spikes in message volume whenever:
- SELLAS publishes a clinical update (REGAL, SLS009),
- Unusual options reports highlight large call flows,
- Articles discuss “why retail is still bullish” after price spikes.
The sentiment tag often flips between “Bullish” and “Neutral”, reflecting both strong upside expectations and awareness of trial risk.
4.2 Reddit & deep-dive communities
The dedicated subreddit r/sellaslifesciences hosts long-form posts on:
- REGAL design and enrollment dynamics (how fast events accumulate, CR2 vs CR2p mix),
- Comparisons of GPS data with other WT1 and vaccine programs,
- OS curve modeling and “what-if” scenarios (e.g., impact of later enrollment, censoring, drop-outs).
In r/options and broader trading subs, SLS appears as a textbook example of “binary biotech” with options and short interest that can produce violent moves on news.
4.3 Options flow
Reports of “unusual options activity” in SLS are frequent: single-day call volumes north of 15–20k contracts, put/call volume ratios near zero, and notable open interest in out-of-the-money calls around expected catalyst windows. This is consistent with speculative positioning by traders seeking leveraged exposure to REGAL.
Takeaway (EN): social and options data confirm that SLS trades as a sentiment-heavy, catalyst-driven
name. News will not be digested calmly; instead it will be amplified by the structure of positioning on both sides.
5. Analyst targets – numbers (not advice)
Across major data platforms, 12-month analyst targets for SLS are tightly clustered:
- Average around 6.8–7.1 USD.
- Low end around 6.0 USD, high end around 7.5 USD.
- Most labels (“rating”) fall into “Buy” or “Strong Buy”; one or more independent services keep a Sell-equivalent rating.
These are scenario-based targets: they broadly assume REGAL is not a complete failure and that SLS009 continues to support a second pillar of value. None of this is guaranteed; negative REGAL data would likely force analysts to cut their targets sharply, while a strong/regulatory-friendly readout might push them higher.
We include these targets because they shape how many readers and market participants perceive “fair value” – not because we endorse them.
6. Fundamentals & risk map
6.1 Balance sheet snapshot
Key points:
- Cash & equivalents: ≈44.3M USD at 30 Sep 2025.
- Warrant exercise proceeds: ≈29.1M USD in October 2025.
- Net loss 9M 2025: ≈19.2M USD (improving vs 24.1M USD in 9M 2024).
- R&D expenses trending lower year-on-year; essentially no financial debt.
This gives SELLAS a reasonable runway through the REGAL catalyst and early SLS009 expansion. It does not negate future dilution risk, but it reduces near-term insolvency concerns.
6.2 Scenario grid (informational only)
Bull / upside
- REGAL shows clear, robust OS benefit; regulators respond favorably.
- GPS moves toward BLA; SLS009 continues to deliver strong data.
- Short squeeze and call-driven flows magnify upside in the short term.
Base / balanced
- REGAL positive but modest; market re-rates SLS, then normalizes.
- SLS009 keeps de-risking, but commercial visibility remains mid-term.
- Further raises occur at better prices but still dilute existing holders.
Bear / downside
- REGAL misses; GPS thesis breaks or weakens materially.
- Stock re-prices sharply down; funding becomes more difficult.
- SLS009 becomes the main asset but needs years and capital to fully prove itself.
Structural risks
- Regulatory risk (FDA/EMA decisions).
- Financing risk (pre-revenue biotech in volatile markets).
- Macro/sector risk (risk-off phases, biotech sentiment swings).
Bottom line (EN): SLS is a leveraged bet on a pivotal trial with a promising backup asset
and an acceptable cash position. This is a map of facts and risks, not a recommendation. Readers should
apply their own risk management and judgment.
7. Disclaimers (EN)
This report is for informational and educational purposes only. It does not constitute investment advice, an offer or a solicitation to buy or sell any security. All data and interpretations are derived from public sources as of the time of writing and may change without notice. Clinical, regulatory and financial outcomes can differ materially from expectations.
Biotech investing, especially in small-cap, late-stage companies without approved products, is inherently risky and volatile. Readers should perform their own due diligence and, where appropriate, consult a licensed financial adviser before making any investment decisions.
For full legal and risk disclosures of Merlintrader trading Blog, please see: https://merlintrader.com/disclaimer/ and https://merlintrader.com/condizioni-duso-e-info-privacy/.
Biotech Catalyst Calendar – stay ahead of the dates
To track REGAL’s final analysis timing and other upcoming PDUFA / data readouts, you can use the Biotech Catalyst Calendar on Merlintrader. It aggregates key FDA decisions, clinical readouts and corporate events in a single, continuously updated view designed for catalyst traders and long-term investors.
Open the Biotech Catalyst CalendarExecutive Summary (IT)
SELLAS Life Sciences (SLS) è una biotech oncologica in fase avanzata centrata su due asset: GPS, vaccino WT1 in fase 3 REGAL (mantenimento in AML CR2), e SLS009, inibitore selettivo di CDK9 con dati di fase 2 positivi all’ASH 2025 in AML-MR recidivata/refrattaria dopo venetoclax.
L’azienda non ha ancora prodotti approvati: il valore a breve termine è dominato da un evento binario – l’analisi finale di REGAL (OS a 80 eventi) – mentre SLS009 sta costruendo un “secondo pilastro” credibile nel medio termine. La cassa (~73M USD) e l’assenza di debito importante mitigano il rischio strutturale, ma non eliminano il rischio clinico.
Il titolo è molto seguito da retail e opzionisti (Stocktwits, Reddit, r/options), con short interest elevato e flussi call-heavy. I target degli analisti (6–7,5 USD) riflettono scenari favorevoli, non certezze. Questo report è solo informativo, non è un consiglio operativo.
1. Panoramica aziendale
SELLAS si posiziona nella nicchia delle terapie WT1-mirate e degli inibitori di CDK9. GPS punta a consolidare la remissione in AML (CR2), potenzialmente espandibile ad altri tumori WT1-positivi; SLS009 mira a colpire tumori “dipendenti” dalla trascrizione di geni pro-sopravvivenza come MCL1.
La società ha collaborazioni con Memorial Sloan Kettering, GenFleet e 3D Medicines, oltre a combinazioni con Merck e BMS nei tumori solidi (Keytruda, Opdivo), che aggiungono una dimensione strategica al di là dell’AML.
2. Pipeline: GPS & SLS009
2.1 GPS – vaccino WT1
In fase 2 su AML CR2, GPS ha mostrato un prolungamento marcato della sopravvivenza globale rispetto al controllo, con OS mediana ~21 mesi vs ~5,4 mesi. Il profilo di sicurezza è risultato favorevole, con soprattutto reazioni locali di basso grado. Questi dati sono alla base di REGAL, studio di fase 3 OS-driven.
Nei tumori solidi (ovario, mesotelioma), combinazioni GPS + checkpoint hanno fornito segnali di attività e controllo di malattia superiori alle attese in setting molto difficili, suggerendo che la piattaforma WT1 possa avere applicazioni più ampie nel tempo.
2.2 SLS009 – inibitore CDK9
SLS009 ha mostrato in fase 2 (ASH 2025) ORR complessiva nell’ordine del 40–50% in AML-MR r/r post VEN, con OS mediana nel sottogruppo meno pre-trattato attorno ai 9 mesi (vs ~2,5–3 mesi attesi storicamente), e un profilo di tollerabilità compatibile con la combinazione con azacitidina e venetoclax.
L’FDA ha fornito indicazioni per uno sviluppo in front-line AML ad alto rischio: se i dati futuri confermeranno il segnale, SLS009 potrebbe diventare un asset chiave anche in scenari meno dipendenti da REGAL.
3. Catalyst REGAL – cosa guarda il mercato
REGAL è lo snodo principale: analisi finale OS a 80 decessi, dopo un interim positivo a 60 eventi. Un risultato chiaramente positivo (beneficio OS robusto) potrebbe avviare il percorso verso un BLA e cambiare drasticamente il profilo di rischio/percezione del titolo. Un risultato negativo o debole metterebbe GPS in secondo piano e sposterebbe il focus quasi completamente su SLS009.
L’intreccio tra catalyst binario, short interest elevato e attività massiccia su opzioni e forum fa sì che la volatilità al momento dei dati sia quasi garantita, nel bene o nel male.
4. Social & retail: Stocktwits, Reddit, opzioni
Su Stocktwits SLS è tra i ticker biotech più seguiti, con newsfeed dedicato e picchi di messaggi ad ogni PR clinico o alert su volumi opzioni. Su Reddit (r/sellaslifesciences) circolano analisi molto dettagliate su REGAL, curve di sopravvivenza e possibili esiti; in r/options il titolo viene citato come esempio di “micro-cap binary biotech” con flussi call estremi e potenziale short squeeze.
In sintesi, la narrativa online è:
- Bullish retail: punta sulla combinazione REGAL + SLS009 e sullo short interest per un potenziale movimento esplosivo.
- Bear: insiste sulla storia complicata dei vaccini oncologici, sulla micro-capitalizzazione e sul rischio di diluizione futura.
Per un lettore questo significa che il prezzo non riflette solo i fondamentali, ma anche l’inerzia dei flussi social e delle posizioni speculative.
5. Target analisti (senza consigli)
Gli aggregatori principali riportano target medi a 12 mesi intorno a 6,8–7,1 USD, con un range complessivo 6–7,5 USD, ottenuti da 3–4 analisti specializzati. Si tratta di target basati su scenari di successo (o quantomeno non fallimento) di REGAL e prosecuzione positiva di SLS009. Un esito negativo di REGAL ridurrebbe verosimilmente questi target; un esito molto forte potrebbe portarli ad essere rivisti al rialzo.
Il report qui non appoggia né contesta questi numeri: li riporta perché fanno parte del “contesto informativo” in cui il titolo viene scambiato.
6. Fondamentali & rischio (IT)
SELLAS arriva al catalyst con cassa intorno a 73M USD, assenza di debito rilevante, perdita netta in miglioramento e partnership che potrebbero portare milestone e royalties in futuro. È un profilo di bilancio relativamente solido per una micro-cap biotech.
Il vero rischio, però, resta quello binario legato a REGAL. La presenza di SLS009 e la cassa disponibile servono da airbag, non da garanzia. Chi guarda il titolo deve accettare a priori la possibilità di scenari estremi sia al rialzo che al ribasso, e valutare se questo tipo di rischio è compatibile con il proprio profilo.
Bottom line (IT): SLS è una scommessa “trial-centrica” con un secondo asset in crescita e fondamentali
non fragili. Questo testo ha il solo scopo di mappare dati e rischi; la decisione se e come esporsi resta una
scelta personale, che dovrebbe essere presa solo dopo aver considerato attentamente la propria tolleranza al rischio.
7. Avvertenze legali (IT)
Le informazioni riportate derivano da fonti pubbliche ritenute affidabili (filing SEC, comunicati e presentazioni ufficiali, principali outlet finanziari), ma possono contenere errori o imprecisioni e non pretendono di essere esaustive. I risultati clinici, regolatori e finanziari possono differire in modo sostanziale da quanto atteso. Questo contenuto non costituisce consulenza finanziaria, né raccomandazione di investimento.
Per le note legali complete di Merlintrader si vedano: https://merlintrader.com/disclaimer/ e https://merlintrader.com/condizioni-duso-e-info-privacy/.
Biotech Catalyst Calendar – resta aggiornato sulle date chiave
Per seguire REGAL e le altre scadenze (PDUFA, letture dati) nel biotech puoi usare il Biotech Catalyst Calendar di Merlintrader, che aggrega gli eventi principali in un’unica vista aggiornata.
Apri il Biotech Catalyst CalendarSELLAS – REGAL Phase 3 Update (December 29, 2025)
Event-driven update on the Phase 3 REGAL trial of GPS in AML CR2: 72 / 80 OS events reached, study remains blinded, no new efficacy analysis performed, and the final readout window shifts from YE 2025 to an event-driven 2026 timeframe. Bilingual EN/IT toggle below.
8. REGAL update – December 29, 2025 (72 / 80 events)
8.1 What the new PR actually says
On December 29, 2025, SELLAS Life Sciences released a GlobeNewswire update on the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in AML maintenance (CR2). The company reports that its contract research organization (CRO) has informed SELLAS that, as of December 26, 2025, 72 of the 80 required events (deaths) have occurred in the study. REGAL is an overall-survival (OS) event-driven trial and the final analysis is pre-specified at 80 events.
SELLAS stresses that it remains fully blinded to all efficacy and OS data. The CRO has only communicated the pooled number of events; no data by treatment arm have been shared. Because no new outcome analyses have been performed, this one-time event-count update does not change the statistical analysis plan and does not consume additional alpha – in other words, no new interim efficacy look has taken place.
Earlier guidance (after the positive IDMC recommendation in August 2025 and in the Q3 2025 update) suggested that the 80th event – and therefore the final OS analysis – was anticipated by year-end 2025. With 72 / 80 events as of December 26, that expectation is now clearly obsolete: the REGAL final readout becomes an event-driven 2026 catalyst, with timing fully dependent on when the remaining eight deaths occur.
8.2 Clinical/statistical reading of 72 / 80
Clinically and statistically, slower-than-expected accrual of OS events in a high-risk AML CR2 population is at least consistent with longer survival versus historical benchmarks. In this setting – non–transplant- eligible CR2 patients treated with hypomethylating agents and/or BCL-2 inhibitors – expert commentary typically quotes a median OS of around 8 months.
The fact that REGAL has not reached 80 deaths within the originally anticipated timeframe fits better with “patients live longer than modelled” than with “curves collapse early”, but it does not tell us whether:
- both arms are living longer than expected (patient selection, background care, etc.), or
- one arm (potentially GPS) is pulling the pooled OS curve to the right with a long tail.
SELLAS remains blinded and never states or implies that 72 / 80 “guarantees success”. Any narrative of “slower events = trial definitely positive” is therefore speculation. The solid takeaway is that the timing of events looks more favorable than in the original OS modelling; the binary nature of the REGAL catalyst is unchanged until the unblinded 80-event readout.
8.3 Retail & social sentiment
Outside the official PR, early coverage has mostly consisted of neutral news rewrites on aggregators and broker feeds: they restate the 72 / 80 event count, underline that REGAL remains blinded and flag that the final analysis now shifts into 2026.
In the retail channels:
- On Stocktwits and similar platforms, SLS continues to trade as a classic “event-driven” name with high beta: recent commentary highlights a strong move over the last month, sentiment meters often in the “bullish” zone and high message volume, with the REGAL countdown at center stage.
- In SELLAS-focused Reddit threads, users dissect event timing, discuss potential hazard ratios at 80 events and debate how OS curves might continue to separate with longer follow-up. There is no shortage of posts describing REGAL as a classic “feast or famine” setup: a clearly positive OS result could justify a major re-rating (and re-open the partnership/M&A narrative), while a weak or negative outcome would likely trigger aggressive repricing, leaving SLS009 as the main asset but with a very different equity story in the near term.
8.4 Practical impact on the SLS catalyst map
For this update and for any SLS-related tracker, the December 29, 2025 communication implies:
- the REGAL final OS analysis moves from a “by year-end 2025” expectation to an event-driven H1 2026 window, defined by when the 80th death occurs;
- the statistical integrity of the primary OS endpoint is preserved: the update is based only on pooled event counts, with no additional unblinded efficacy look;
- the risk profile stays the same: SLS remains a high-leverage story centered on REGAL, with SLS009 as a second pillar that is still consolidating.
This block is meant as an add-on specifically focused on the December 29, 2025 REGAL update. It does not change
the analytical framework of the main SLS report; it simply refreshes timing and context based on the latest
official disclosure and visible retail sentiment.
8. Aggiornamento REGAL – 29 dicembre 2025 (72 / 80 eventi)
8.1 Contenuto del nuovo comunicato
Il 29 dicembre 2025 SELLAS Life Sciences ha diffuso, tramite GlobeNewswire, un aggiornamento sul trial pivotal di Fase 3 REGAL con galinpepimut-S (GPS) nel mantenimento dell’AML in seconda remissione completa (CR2). Il CRO che gestisce lo studio ha informato l’azienda che, al 26 dicembre 2025, nel trial si erano verificati 72 degli 80 eventi richiesti (eventi = decessi). REGAL è uno studio di sopravvivenza globale (OS) basato sul numero di eventi e il piano statistico prevede che l’analisi finale venga effettuata solo al raggiungimento di 80 decessi.
SELLAS sottolinea di essere ancora completamente cieca (blinded) sui dati di efficacia e di OS. Il CRO ha comunicato soltanto il numero aggregato di eventi, senza alcuna informazione per braccio. Poiché non è stata eseguita alcuna nuova analisi di outcome, l’azienda precisa che questo aggiornamento una tantum sul conteggio degli eventi non modifica il piano statistico e non comporta alcun consumo aggiuntivo di alfa: in pratica, non c’è stato un nuovo interim di efficacia.
In precedenza (dopo la raccomandazione positiva dell’IDMC di agosto 2025 e nell’update di Q3) SELLAS indicava che l’80° evento – e quindi l’analisi finale di REGAL – era atteso entro fine 2025. Con 72 / 80 eventi al 26 dicembre, quella guidance è ormai chiaramente superata: il readout di REGAL diventa a tutti gli effetti un catalyst event-driven sul 2026, con tempistiche dettate solo dal momento in cui matureranno gli ultimi otto decessi.
8.2 Lettura clinico-statistica del 72 / 80
Dal punto di vista clinico-statistico, una maturazione degli eventi OS più lenta del previsto in una popolazione AML CR2 ad alto rischio è almeno coerente con una sopravvivenza più lunga rispetto ai benchmark storici. Nel comunicato viene ricordato che, per pazienti non eleggibili a trapianto trattati con agenti ipometilanti e/o inibitori BCL-2, la mediana di OS attesa è di circa 8 mesi.
Il fatto che REGAL non sia ancora arrivato agli 80 decessi nella finestra temporale iniziale è più compatibile con “i pazienti vivono più a lungo di quanto modellato” che non con “le curve collassano subito”. Tuttavia questo aggiornamento non ci dice se:
- entrambi i bracci stanno vivendo più a lungo del previsto, oppure
- se uno dei due bracci (ad esempio GPS) sta generando una “coda lunga” che sposta la curva OS complessiva verso destra.
SELLAS resta cieca e non afferma mai che il 72 / 80 “garantisca il successo”. Qualunque narrativa del tipo “eventi che maturano più lentamente = trial sicuramente positivo” resta quindi speculativa. Il punto solido è che la tempistica degli eventi appare più favorevole rispetto all’ipotesi originaria di OS; la natura binaria del catalyst REGAL resta però immutata fino alla pubblicazione dei dati unblinded a 80 eventi.
8.3 Reazione retail e social
Al di fuori del comunicato ufficiale, la copertura iniziale si limita a riassunti piuttosto neutri su aggregatori e feed di trading: viene riportato il dato 72 / 80, si ribadisce che REGAL resta blindato e si evidenzia che l’analisi finale scivola nel 2026.
Nelle community retail:
- Su Stocktwits e piattaforme simili SLS continua a essere trattata come titolo “event-driven” ad alta beta: si sottolineano il forte rialzo dell’ultimo mese, lo stato del sentiment spesso in zona “bullish” e un volume di messaggi elevato, con il countdown REGAL e la natura dell’endpoint OS al centro delle discussioni.
- Nei thread dedicati su Reddit, gli utenti discutono in dettaglio la tempistica degli eventi, scenari di hazard ratio a 80 eventi e possibili evoluzioni delle curve con follow-up più lungo. Non mancano post che definiscono REGAL un caso “feast or famine”: un risultato OS chiaramente positivo potrebbe giustificare un re-rating importante (e riaccendere lo scenario partnership/M&A), mentre un esito debole o negativo porterebbe con grande probabilità a un repricing aggressivo, lasciando SLS009 come asset principale ma con una storia azionaria molto diversa nel breve periodo.
8.4 Effetto pratico sulla mappa catalyst di SLS
Per questo update e per eventuali tracker collegati, l’aggiornamento del 29 dicembre 2025 implica:
- lo spostamento dell’analisi finale di REGAL da una finestra “entro fine 2025” a una finestra event-driven nel primo semestre 2026, definita dal momento in cui verrà raggiunto l’80° decesso;
- la conferma che l’integrità statistica dell’endpoint primario di OS è preservata: l’update si basa solo sul conteggio aggregato degli eventi, senza nuove analisi unblinded;
- il fatto che il profilo di rischio non cambia: SLS resta una storia fortemente trial-centrica, con REGAL come driver principale di breve periodo e SLS009 come secondo pilastro in fase di consolidamento.
Questo blocco è pensato come add-on specifico sull’aggiornamento REGAL del 29 dicembre 2025. Non modifica
l’impostazione generale del report principale su SLS; aggiorna semplicemente tempistiche e contesto alla
luce dell’ultima disclosure ufficiale e del sentiment retail visibile.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
